Cargando…

Anti-PD1 Consolidation in Patients with Hodgkin Lymphoma at High Risk of Relapse after Autologous Stem Cell Transplantation: A Multicenter Real-Life Study

SIMPLE SUMMARY: Autologous stem cell transplantation (ASCT) represents a standard strategy for patients with relapsed and refractory (RR) Hodgkin Lymphoma (HL). Unfortunately, patients displaying some pre-transplant adverse predictors eventually progress, requiring further treatments and several suc...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Filippi, Rosaria, Marcacci, Gianpaolo, Derenzini, Enrico, Musso, Maurizio, Donnarumma, Daniela, Morelli, Emanuela, Patti, Caterina, Maraglino, Alessio Maria Edoardo, Scalone, Renato, Simeone, Luigia, Becchimanzi, Cristina, Mele, Sara, Crisci, Stefania, Morabito, Fortunato, Pinto, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739754/ https://www.ncbi.nlm.nih.gov/pubmed/36497328 http://dx.doi.org/10.3390/cancers14235846

Ejemplares similares

Post-exposure prophylaxis with sotrovimab for Omicron (B.1.1.529) SARS-CoV-2 variant during the aplastic phase of autologous stem cell transplantation
por: Marcacci, Gianpaolo, et al.
Publicado: (2022)

Hodgkin’s lymphoma: post- autologous transplantation consolidation therapy
por: Merli, Francesco, et al.
Publicado: (2020)

Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas
por: Crisci, Stefania, et al.
Publicado: (2019)

Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas
por: Corazzelli, Gaetano, et al.
Publicado: (2011)

Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine‐based high‐dose chemotherapy regimen
por: Musso, Maurizio, et al.
Publicado: (2015)

Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
por: De Filippi, Rosaria, et al.
Publicado: (2021)

Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real‐life experience
por: Massaro, Fulvio, et al.
Publicado: (2021)

Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab
por: Marcacci, Gianpaolo, et al.
Publicado: (2021)

Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy
por: Corazzelli, Gaetano, et al.
Publicado: (2011)

Role of Consolidative Radiation Therapy After Autologous Hematopoietic Cell Transplantation for the Treatment of Relapsed or Refractory Hodgkin Lymphoma
por: Wilke, Christopher, et al.
Publicado: (2017)

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances
por: Derenzini, Enrico, et al.
Publicado: (2011)

P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.
por: Michalka, Jozef, et al.
Publicado: (2022)

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
por: Fedele, Roberta, et al.
Publicado: (2015)

Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma
por: Hoppe, B. S., et al.
Publicado: (2017)

PB2465: ALLOGENEIC HSCT OUTCOMES IN SIX PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS WITH A HISTORY OF OVARIAN CANCER TREATED WITH CHEMOTERAPY AND PARP INHIBITORS
por: Maria Edoardo Maraglino, Alessio, et al.
Publicado: (2023)

The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice
por: Galimberti, Sara, et al.
Publicado: (2019)

Autologous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma
por: Cortez, Afonso José Pereira, et al.
Publicado: (2011)

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
por: Derenzini, E, et al.
Publicado: (2011)

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
por: Derenzini, E, et al.
Publicado: (2014)

Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
por: Nahi, Hareth, et al.
Publicado: (2022)

Impact of HIV infection on consolidative radiotherapy for non-Hodgkin diffuse large B-cell lymphoma
por: Medici, Carolina Trindade Mello, et al.
Publicado: (2020)

Treatment of Hodgkin Lymphoma Relapsed after Autologous Stem Cell Transplantation
por: Domingo-Domènech, Eva, et al.
Publicado: (2020)

Matrix assisted autologous chondrocyte transplantation for cartilage treatment: A systematic review
por: Kon, E., et al.
Publicado: (2013)

Quantitative magnetic resonance imaging in autologous bone marrow transplantation for Hodgkin's disease.
por: Smith, S. R., et al.
Publicado: (1989)

High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease.
por: Philip, T., et al.
Publicado: (1986)

Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy
por: Rapoport, AP, et al.
Publicado: (2002)

Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma
por: Saifi, Omran, et al.
Publicado: (2023)

Consolidation of the LHC Superconducting Magnets and Circuits
por: Tock, J Ph, et al.
Publicado: (2016)

High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.
por: Zulian, G. B., et al.
Publicado: (1989)

Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation
por: Currin, Erin-Siobhain R., et al.
Publicado: (2012)

Current Role of Autologous and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
por: Castagna, Luca, et al.
Publicado: (2015)

Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma
por: Jackson, Zachary, et al.
Publicado: (2020)

Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma
por: van Bruggen, Jaco A. C., et al.
Publicado: (2020)

Autologous Stem Cell Transplantation in Hodgkin Lymphoma—Latest Advances in the Era of Novel Therapies
por: Samara, Yazeed, et al.
Publicado: (2022)

Severe autoimmune pancytopenia after autologous hematopoietic stem cell transplantation for Hodgkin lymphoma
por: Fukui, Yuta, et al.
Publicado: (2022)

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2023)

Is there a role for consolidative radiotherapy in the treatment of aggressive and localized Non-Hodgkin Lymphoma? A systematic review with meta-analysis
por: dos Santos, Lucas Vieira, et al.
Publicado: (2012)

Consolidation radiotherapy for advanced-stage aggressive B-cell non-Hodgkin lymphoma: A systematic review and meta-analysis
por: Yap, Ernie, et al.
Publicado: (2017)

Use of autologous platelet-rich plasma for a delayed consolidation of a tibial fracture in a young donkey
por: FAILLACE, Vanessa, et al.
Publicado: (2017)

Status of the Consolidation of the LHC Superconducting Magnets and Circuits
por: Tock, J Ph, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_elasrlagcu34sr7iftj6cbm2he